ONC_AFT05 PALLAS

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Phase III
NCT02513394
Cancer
Breast
Jeanne Anderson MD
Pfizer
  • Alaska Research
  • Katmai Oncology Group